Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2017
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2017
SUMMARY
According to the recently published report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H2 2017'; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 36 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.
The report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 7, 8, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosed which include indications Solid Tumor, Ovarian Cancer, Breast Cancer, Epithelial Ovarian Cancer, Metastatic Melanoma, Bladder Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Peritoneal Cancer, Pigmented Villonodular Synovitis, Recurrent Glioblastoma Multiforme (GBM), Tenosynovial Giant Cell Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Soft Tissue Sarcoma, Acral Lentiginous Melanoma, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Inflammation, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Papillary Thyroid Cancer, Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Crohn's Disease (Regional Enteritis), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Endometrial Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gliosarcoma, Hematological Tumor, Lentigo Maligna Melanoma, Liposarcoma, Lung Adenocarcinoma, Malignant Ascites, Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Osteolysis, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Renal Failure, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified, Uveal Melanoma and Von Hippel-Lindau Syndrome.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H2 2017'; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 36 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.
The report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H2 2017' outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 7, 8, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosed which include indications Solid Tumor, Ovarian Cancer, Breast Cancer, Epithelial Ovarian Cancer, Metastatic Melanoma, Bladder Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Peritoneal Cancer, Pigmented Villonodular Synovitis, Recurrent Glioblastoma Multiforme (GBM), Tenosynovial Giant Cell Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Soft Tissue Sarcoma, Acral Lentiginous Melanoma, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Inflammation, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Papillary Thyroid Cancer, Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Crohn's Disease (Regional Enteritis), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Endometrial Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gliosarcoma, Hematological Tumor, Lentigo Maligna Melanoma, Liposarcoma, Lung Adenocarcinoma, Malignant Ascites, Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Osteolysis, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Renal Failure, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified, Uveal Melanoma and Von Hippel-Lindau Syndrome.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Overview
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AB Science SA
Amgen Inc
Array BioPharma Inc
BCI Pharma
Bristol-Myers Squibb Co
CrystalGenomics Inc
CTI BioPharma Corp
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd
GigaGen Inc
Hutchison MediPharma Ltd
Ignyta Inc
Nerviano Medical Sciences Srl
Novartis AG
Pfizer Inc
Plexxikon Inc
SignalChem Lifesciences Corp
Syndax Pharmaceuticals Inc
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles
AMG-820 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-382 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atezolizumab + emactuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLZ-945 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabiralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCC-3014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emactuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emactuzumab + RG-7876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-2580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3022855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize CSF1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride + pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-0360324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexidartinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-5622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-73086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibitor CSF1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CSF-1R for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNDX-6352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2017: Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine
Nov 16, 2017: Pfizer Receives FDA Approval For Sutent (Sunitinib Malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
Nov 13, 2017: Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer 32nd Annual Meeting
Nov 11, 2017: Syndax Announces Presentation of Clinical Trial Data on Drug Candidate SNDX-6352 at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Nov 09, 2017: Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Nov 07, 2017: Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data
Nov 07, 2017: Syndax to Present Data On Drug Candidate SNDX-6352 at SITC 32nd Annual Scientific Meeting
Oct 31, 2017: Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor
Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight
Oct 11, 2017: Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Sep 28, 2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017
Sep 19, 2017: Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT in Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery
Sep 14, 2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment
Sep 11, 2017: Ignyta Provides Update on Investigational Lung Cancer Drug RXDX-105 at ESMO 2017 Congress
Sep 07, 2017: Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Overview
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AB Science SA
Amgen Inc
Array BioPharma Inc
BCI Pharma
Bristol-Myers Squibb Co
CrystalGenomics Inc
CTI BioPharma Corp
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd
GigaGen Inc
Hutchison MediPharma Ltd
Ignyta Inc
Nerviano Medical Sciences Srl
Novartis AG
Pfizer Inc
Plexxikon Inc
SignalChem Lifesciences Corp
Syndax Pharmaceuticals Inc
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles
AMG-820 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARRY-382 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
atezolizumab + emactuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLZ-945 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabiralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCBX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCC-3014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELB-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emactuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emactuzumab + RG-7876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-2580 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3022855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize CSF1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MSB-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride + pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-0360324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexidartinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-5622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-73086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-6527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibitor CSF1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CSF-1R for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNDX-6352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sunitinib malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Nov 21, 2017: Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine
Nov 16, 2017: Pfizer Receives FDA Approval For Sutent (Sunitinib Malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
Nov 13, 2017: Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer 32nd Annual Meeting
Nov 11, 2017: Syndax Announces Presentation of Clinical Trial Data on Drug Candidate SNDX-6352 at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
Nov 09, 2017: Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors
Nov 07, 2017: Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data
Nov 07, 2017: Syndax to Present Data On Drug Candidate SNDX-6352 at SITC 32nd Annual Scientific Meeting
Oct 31, 2017: Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor
Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight
Oct 11, 2017: Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Sep 28, 2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017
Sep 19, 2017: Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT in Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery
Sep 14, 2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment
Sep 11, 2017: Ignyta Provides Update on Investigational Lung Cancer Drug RXDX-105 at ESMO 2017 Congress
Sep 07, 2017: Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1)
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AB Science SA, H2 2017
Pipeline by Amgen Inc, H2 2017
Pipeline by Array BioPharma Inc, H2 2017
Pipeline by BCI Pharma, H2 2017
Pipeline by Bristol-Myers Squibb Co, H2 2017
Pipeline by CrystalGenomics Inc, H2 2017
Pipeline by CTI BioPharma Corp, H2 2017
Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Pipeline by Eli Lilly and Co, H2 2017
Pipeline by Elsalys Biotech SAS, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by GigaGen Inc, H2 2017
Pipeline by Hutchison MediPharma Ltd, H2 2017
Pipeline by Ignyta Inc, H2 2017
Pipeline by Nerviano Medical Sciences Srl, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Pfizer Inc, H2 2017
Pipeline by Plexxikon Inc, H2 2017
Pipeline by SignalChem Lifesciences Corp, H2 2017
Pipeline by Syndax Pharmaceuticals Inc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Dormant Products, H2 2017 (Contd.2), H2 2017
Dormant Products, H2 2017 (Contd.3), H2 2017
Dormant Products, H2 2017 (Contd.4), H2 2017
Dormant Products, H2 2017 (Contd.5), H2 2017
Dormant Products, H2 2017 (Contd.6), H2 2017
Discontinued Products, H2 2017
Discontinued Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1)
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AB Science SA, H2 2017
Pipeline by Amgen Inc, H2 2017
Pipeline by Array BioPharma Inc, H2 2017
Pipeline by BCI Pharma, H2 2017
Pipeline by Bristol-Myers Squibb Co, H2 2017
Pipeline by CrystalGenomics Inc, H2 2017
Pipeline by CTI BioPharma Corp, H2 2017
Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Pipeline by Eli Lilly and Co, H2 2017
Pipeline by Elsalys Biotech SAS, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by GigaGen Inc, H2 2017
Pipeline by Hutchison MediPharma Ltd, H2 2017
Pipeline by Ignyta Inc, H2 2017
Pipeline by Nerviano Medical Sciences Srl, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Pfizer Inc, H2 2017
Pipeline by Plexxikon Inc, H2 2017
Pipeline by SignalChem Lifesciences Corp, H2 2017
Pipeline by Syndax Pharmaceuticals Inc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd.1), H2 2017
Dormant Products, H2 2017 (Contd.2), H2 2017
Dormant Products, H2 2017 (Contd.3), H2 2017
Dormant Products, H2 2017 (Contd.4), H2 2017
Dormant Products, H2 2017 (Contd.5), H2 2017
Dormant Products, H2 2017 (Contd.6), H2 2017
Discontinued Products, H2 2017
Discontinued Products, H2 2017 (Contd.1), H2 2017
Discontinued Products, H2 2017 (Contd.2), H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
AB Science SA
Amgen Inc
Array BioPharma Inc
BCI Pharma
Bristol-Myers Squibb Co
CrystalGenomics Inc
CTI BioPharma Corp
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd
GigaGen Inc
Hutchison MediPharma Ltd
Ignyta Inc
Nerviano Medical Sciences Srl
Novartis AG
Pfizer Inc
Plexxikon Inc
SignalChem Lifesciences Corp
Syndax Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
COMPANIES MENTIONED
AB Science SA
Amgen Inc
Array BioPharma Inc
BCI Pharma
Bristol-Myers Squibb Co
CrystalGenomics Inc
CTI BioPharma Corp
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
Elsalys Biotech SAS
F. Hoffmann-La Roche Ltd
GigaGen Inc
Hutchison MediPharma Ltd
Ignyta Inc
Nerviano Medical Sciences Srl
Novartis AG
Pfizer Inc
Plexxikon Inc
SignalChem Lifesciences Corp
Syndax Pharmaceuticals Inc
